Play Video This will play a video - Video thumbnail

5-year Reintervention Data

IN.PACT™ Admiral™ Drug-Coated Balloon (DCB) — the only DCB proven through 5 years.1
Alert Indications, Safety, and Warnings

Highest Patency Benefit through 3 Years‡2

Compare to Other DCBS

Lowest CD-TLR Rate and Mortality through 5 Years1,3

View Publication

Most Publications for a DCB§

See Comparison

A Physician's Perspective

Watch to learn why IN.PACT Admiral is Dr. Ehrin Armstrong's DCB of choice.

Play Video This will play a video - Video featuring the reasons why IN.PACT Admiral drug-coated balloon is Dr. Ehrin Armstrong's DCB of choice

75% of Patients Reintervention-free at 5 Years.1 

This matters now more than ever.||

IN.PACT Admiral DCB provides 180 days of sustained drug release in the tissue.4

Chart showing the duration of paclitaxel in the tissue up to 180 days after index procedure

See the Difference

Listen to Dr. Stefan Tunev explain how sustained delivery is key to the unique clinical performance of the IN.PACT Admiral drug-coated balloon.
More information (see more) Less information (see less)

Meet Robert Canterbury, who was diagnosed with peripheral artery disease (PAD), and see how IN.PACT Admiral DCB helped get him back on his feet.
More information (see more) Less information (see less)

IN.PACT Admiral drug-coated balloon shown in 200 and 250 mm lengths

Going the Distance

Learn More

Connect With Us

CardioVascular Lifeline
Customer Support
+1-763-526-7890
rs.cstechsupport@medtronic.com

Orders
+1-763-514-8510
rs.cuvasorders@medtronic.com

24-hour Technical Support
+1-763-514-4000 (worldwide)

*

Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.

†

Based on sales units sold since CE Mark. Units sold divided by units per procedure.

‡

Primary patency not assessed after 3 years.

§

Data and additional comparative data on file with Medtronic.

||

The potential for fewer visits to a healthcare provider may reduce the exposure to COVID-19-related risks.

Ranger DCB is not approved for commercial use in the United States.

References

1

IN.PACT Admiral 5Y data: Laird JA, Schneider PA, Jaff MR, et al. Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions. Circ Cardiovasc Interv. June 2019;12(6):e007702.

2

Schneider PA, Laird J, Tepe G, et al. Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries: Long-Term Results of the IN.PACT SFA Randomized Trial. Circ Cardiovasc Interv. January 2018;11(1):e005891.   

3

Based on the mortality data from the LEVANT 2 IDE in the Lutonix™* DCB IFU (BAW1387400r6) and the IN.PACT SFA Trial in the IN.PACT™ Admiral™ DCB IFU (M052624T001).

4

Virmani, R. Charing Cross, 2016: Arterial wall response to drug coated balloon, data on file.

5

Gongora CA, Shibuya M, Wessler JD, et al. Impact of Paclitaxel Dose on Tissue Pharmacokinetics and Vascular Healing: A Comparative Drug-Coated Balloon Study in the Familial Hypercholesterolemic Swine Model of Superficial Femoral In-Stent Restenosis. JACC Cardiovasc Interv. July 2015;8(8):1115-1123.

6

Spectranetics Stellarex 035 DCB Advisory Panel Briefing Package. June 2019.